Trials / Completed
CompletedNCT04293094
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Volastra Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 650 | AMG 650 administered orally as a tablet. |
Timeline
- Start date
- 2020-03-11
- Primary completion
- 2022-10-24
- Completion
- 2023-02-15
- First posted
- 2020-03-03
- Last updated
- 2023-08-24
Locations
22 sites across 7 countries: United States, Australia, Belgium, Canada, Italy, Japan, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04293094. Inclusion in this directory is not an endorsement.